企查查显示，成立以来，正雅齿科已获得数轮融资，投资者包括敦鸿资产、好臻投资、华润资本、元生创投、泰康投资、辰德资本、元生创投、前海母基 金、承树投资等。 | 2019-03-24 ● 融资 数亿元 | | 新 | | --- | --- | --- | | C轮 | 中金启辰、元生创投、前海母基金、基石 | | | 本、高科新浚 | | | | 2017-09-01 ● 融资 5000万元 | | | | B轮 | 中国东方资产、元生创投、辰德资本 | | | 2015-09-01 ● 金额未披露 | | | | ASC 投资方未披露 | | | | 辅导 对 象 | 浙江正雅齿科股份有限公司 | | --- | --- | | 成 立 日 期 | 2010-12-28 | | 注册资本 | 36,000 万元 | | 注册地址 | 浙江省嘉兴市南湖区大桥镇兴业路 | | 控 股 股 东 及 持 股 比 例 | 公司创始人姚峻峰直接持有发行人 持有公司 9.07%的股份,同时通过 合伙)间接持有公司 3.49%的股份 | | | (有限合伙)间接持有公司 2.57% | | | 企业(有限合伙)间接持有公司 ...

Core Viewpoint - Angelalign (06699) has seen a stock price increase of over 5%, currently trading at 68.7 HKD, with a transaction volume of 23.6952 million HKD, following the announcement of receiving the MDR-CE certification from TÜV Süd [1] Group 1: Certification and Market Impact - Angelalign recently held a certification ceremony in Shanghai, where TÜV Süd officially awarded the MDR-CE certificate, indicating compliance with EU medical device regulations [1] - The MDR-CE certification signifies that Angelalign's products meet the EU's stringent legal requirements for safety, effectiveness, and lifecycle compliance, enhancing international recognition and market credibility [1] - CEO Hu Jiezhang stated that after over two years of international development, Angelalign's overseas business has grown rapidly, with international cases accounting for over 50% of total cases in the first half of this year, covering over 60 countries and regions [1] Group 2: Strategic Importance - The receipt of the CE certification marks a significant milestone in Angelalign's globalization process, further solidifying the company's competitive foundation in the international invisible orthodontics market [1]

获得MDR-CE证书代表时代天使产品完全满足欧盟对医疗器械安全性、有效性及全生命周期合规性的强 制性法律要求，具有极高的国际认可度与市场公信力。时代天使CEO胡杰章在授证仪式上表示，经过两 年多的国际化发展，时代天使海外业务增长迅速，今年上半年的国际病例数占总案例数比例已超过 50%，业务覆盖60多个国家和地区。此次获得CE认证，是时代天使全球化进程中的重要里程碑，也将 进一步夯实公司在国际隐形矫治市场中的竞争基础。 消息面上，据时代天使官网消息，近日，时代天使在上海举办MDR-CE证书授证仪式。T V南德意志集 团(以下简称"T V南德")在授权仪式上为时代天使正式颁发CE实体证书。此次获得国际权威欧盟公告机 构(Notified Body)的认可，标志着时代天使隐形矫治相关产品在安全性、有效性及合规性方面全面符合 欧盟医疗器械法规要求，也意味着时代天使在高标准海外市场准入上迈出重要一步。 时代天使(06699)涨超5%，截至发稿，涨4.57%，报68.7港元，成交额2369.52万港元。 ...

Core Insights - Angelalign Biotechnology Co., Ltd. has received the MDR-CE certification, marking a significant step in meeting EU medical device regulations and enhancing its market credibility [1][2] Group 1: Certification and Compliance - The MDR-CE certificate was awarded by T V Süddeutsche Group, a globally recognized Notified Body in medical device certification, indicating that Angelalign's products meet stringent EU safety, efficacy, and compliance standards [1] - The certification process involved rigorous multi-dimensional reviews of product technology, clinical evaluation, quality management systems, and post-market surveillance, reflecting the high standards of the EU's Medical Device Regulation (MDR) [1] Group 2: Strategic Positioning - The CEO of Angelalign emphasized that the CE certification is a result of the company's long-term investment in product development, quality systems, and compliance capabilities, alongside the strict requirements set by T V Süddeutsche [2] - Since initiating its globalization strategy, Angelalign has prioritized entry into developed markets such as Europe and the U.S., necessitating alignment with the highest regulatory standards and local medical practices [2]

Group 1 - The core viewpoint of the news is that Times Angel Biotechnology Co., Ltd. has received the MDR-CE certification from TÜV Rheinland, marking a significant step in meeting EU medical device regulations and enhancing its market credibility in high-standard overseas markets [1][2] - The MDR-CE certification indicates that Times Angel's products comply with the EU's stringent safety, effectiveness, and compliance requirements for medical devices, which involves a rigorous multi-dimensional review process by a recognized Notified Body [1] - TÜV Rheinland is recognized globally for its authority in medical device certification, and the MDR-CE certification is considered one of the most stringent regulatory frameworks worldwide [1] Group 2 - The CEO of Times Angel stated that the CE certification is a result of the company's long-term investment in product development, quality systems, and compliance capabilities, as well as the strict requirements set by TÜV Rheinland [2] - Since initiating its globalization strategy, Times Angel has prioritized entry into developed markets such as Europe and the United States, necessitating alignment with the highest standards in regulations, data security, product quality, and certification processes [2]

本报讯 （记者李春莲）近日，时代天使生物科技有限公司（以下简称"时代天使"）在上海举办MDR- CE证书授证仪式。TV南德意志集团（以下简称"TV南德"）代表团专程莅临现场，为时代天使正式颁发 CE实体证书。此次获得国际权威欧盟公告机构（Notified Body）的认可，标志着时代天使隐形矫治相 关产品在安全性、有效性及合规性方面全面符合欧盟医疗器械法规要求，也意味着时代天使在高标准海 外市场准入上迈出重要一步。 TV南德是欧盟官方授权的公告机构，在医疗器械认证领域具有全球公认的专业权威性。本次时代天使 所获的MDR-CE证书，是依据欧盟《医疗器械法规》（Medical Device Regulation，MDR）颁发的准入 凭证，MDR也是全球最严格的医疗器械监管体系之一，获得这项证书需经过公告机构对产品技术、临 床评价、质量管理体系及上市后监督等多个维度的系统性、多轮次严格审核，流程严谨、复杂，标准极 高。因此，获得MDR-CE证书代表时代天使产品完全满足欧盟对医疗器械安全性、有效性及全生命周期 合规性的强制性法律要求，具有极高的国际认可度与市场公信力。 （文章来源：证券日报） 时代天使CEO胡杰章表示 ...

Core Viewpoint - Angelalign (06699) reported strong mid-year performance with significant revenue and profit growth, driven by international market expansion and increased case numbers [1] Financial Performance - Revenue for the first half of the year reached $161.4 million, a year-on-year increase of 33.1% [1] - Adjusted net profit was $19.5 million, reflecting an 84.8% increase compared to the previous year [1] - Profit attributable to shareholders was $14.64 million, showing a substantial year-on-year growth of 362.65% [1] Operational Highlights - Total cases of invisible orthodontics increased by 47.7% year-on-year, reaching approximately 225,800 cases [1] - International market cases surged by 103.5% year-on-year, totaling about 117,200 cases, surpassing the domestic market's 108,600 cases [1] - The management raised the annual case volume guidance to between 490,000 and 500,000, indicating a year-on-year growth of 36% to 39% [1] Profitability Metrics - Gross margin remained stable at 62.4%, consistent with the same period last year [1] - Domestic business maintained good profitability despite strategic price adjustments [1] - Overseas gross margin improved from 58.3% in the previous year to 61.2% [1]

Group 1 - The core viewpoint of the article highlights that Times Angel (06699) has shown strong performance in the first half of the year, with a revenue growth of 33% driven primarily by rapid expansion in overseas markets [1] - The report anticipates that the strong growth in cases for Times Angel will continue in the second half of the year, maintaining a "Buy" rating and raising the target price from HKD 69.55 to HKD 86.47 [1] - The total number of invisible orthodontic cases achieved by the group in the first half reached 225,800, representing a year-on-year increase of 48%, surpassing the bank's annual expectation of 517,000 and exceeding the historical average of 410,000 [1] Group 2 - The net profit margin attributable to the company significantly improved to 9.1%, an increase of 6.5 percentage points year-on-year, benefiting from effective cost control measures, delayed hiring, and postponed commissioning of overseas production facilities [1]

Core Viewpoint - Angelalign (06699) reported strong financial performance for the first half of 2025, with significant increases in revenue, profit, and case numbers for invisible orthodontics [1] Financial Performance - Revenue reached $161.4 million, a year-on-year increase of 33.1% [1] - Gross profit was approximately $100 million, reflecting a 32.9% year-on-year growth [1] - Adjusted net profit amounted to $19.5 million, up 84.8% compared to the previous year [1] - Profit attributable to the company's owners was $14.64 million, showing a remarkable year-on-year increase of 362.65% [1] - Earnings per share stood at $0.09, with a special interim dividend of HKD 0.46 per share [1] Operational Highlights - The total number of invisible orthodontic cases grew by 47.7% year-on-year, reaching approximately 225,800 cases [1] - International market cases accounted for about 117,200, while cases in the Chinese market were approximately 108,600 [1]

Core Viewpoint - Angelalign (06699) reported strong financial results for the first half of 2025, showcasing significant growth in revenue, profit, and case numbers in the invisible orthodontics market [1] Financial Performance - Revenue reached $161.4 million, a year-on-year increase of 33.1% [1] - Gross profit was approximately $100 million, reflecting a 32.9% year-on-year growth [1] - Adjusted net profit amounted to $19.5 million, up 84.8% compared to the previous year [1] - Profit attributable to shareholders was $14.64 million, marking a substantial increase of 362.65% year-on-year [1] - Earnings per share stood at $0.09, with a special interim dividend of HKD 0.46 per share [1] Market Performance - The total number of invisible orthodontic cases grew by 47.7% year-on-year, reaching approximately 225,800 cases [1] - International market cases accounted for about 117,200, while cases in the Chinese market were approximately 108,600 [1]